Lasofoxifene Explored in ESR1-Mutated ER+/HER2- Breast Cancer

Rachel Narozniak
Published: Thursday, Sep 12, 2019
Dr Matthew Goetz

Matthew Goetz, MD
Investigators are exploring whether lasofoxifene can stop disease progression in women with advanced or metastatic estrogen receptor (ER)–positive, HER2-negative breast cancer with an ESR1 mutation in the multicenter phase II ELAINE trial (NCT03781063).

“However, like any other agent, disease will eventually progress on CDK4/6 inhibitors,” Goetz said. “[Resistance] is a major clinical problem. We need new approaches to treat these women.”

Figure. Lasofoxifene Versus Fulvestrant Phase II ELAINE Trial (Click to Enlarge)

Lasofoxifene is a selective ER modulator (SERM) that binds to the ER with high affinity to inhibit estrogen-dependent cancer cell proliferation in ER-expressing cancers.4 Like lasofoxifene, tamoxifen is a SERM that binds to the ER to promote antiestrogenic activity. The nonsteroidal compound is a recommended treatment option for both pre- and postmenopausal women with breast cancer and is most commonly used in the adjuvant setting in patients with early-stage disease to reduce the risk of recurrence. The National Comprehensive Cancer Network guidelines recommend 5 to 10 years of treatment with tamoxifen.5

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication